Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models
Abstract
Purpose: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA-mutant (BRCAMUT) high-grade serous ovarian cancers (HGSOC). We hypothesized that PARPi increases dependence on ATR/CHK1 such that combination PARPi with ATR/CHK1 blockade results in increased cell death and tumor regression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 14, 2017
- Source ID
- 10.1158/1078-0432.ccr-16-2273
Entities
People
- Aaron George
- Clemens Krepler
- Eric J. Brown
- Fiona Simpkins
- Hyoung Kim
- Mark A. Morgan
- Meenhard Herlyn
- Rugang Zhang
- Ryan L. Ragland
- Stavros Rafail
Organizations
- United States Department of Defense
- University of Pennsylvania